Rationale: Accurate peri-operative risk prediction is an essential element of clinical practice. Various risk stratification tools for assessing patients' risk of mortality or morbidity have been developed and applied in clinical practice over the years. This review aims to outline essential characteristics (predictive accuracy, objectivity, clinical utility) of currently available risk scoring tools for hip fracture patients. Methods: We searched eight databases; AMED, CINHAL, Clinical Trials.gov, Cochrane, DARE, EMBASE, MEDLINE and Web of Science for all relevant studies published until April 2015. We included published English language observational studies that considered the predictive accuracy of risk stratification tools for patients with fragility hip fracture. Results: After removal of duplicates, 15,620 studies were screened. Twenty-nine papers met the inclusion criteria, evaluating 25 risk stratification tools. Risk stratification tools considered in more than two studies were; ASA, CCI, E-PASS, NHFS and O-POSSUM. All tools were moderately accurate and validated in multiple studies; however there are some limitations to consider. The E-PASS and O-POSSUM are comprehensive but complex, and require intraoperative data making them a challenge for use on patient bedside. The ASA, CCI and NHFS are simple, easy and inexpensive using routinely available preoperative data. Contrary to the ASA and CCI which has subjective variables in addition to other limitations, the NHFS variables are all objective. Conclusion: In the search for a simple and inexpensive, easy to calculate, objective and accurate tool, the NHFS may be the most appropriate of the currently available scores for hip fracture patients. However more studies need to be undertaken before it becomes a national hip fracture risk stratification or audit tool of choice. 
Introduction
Fragility hip fractures among the elderly constitute a significant global public health problem. Risk scoring to identify high risk patients is strongly encouraged [1] . It aims to provide prognostic information based on available patient data. This in-turn allows: (a) increased objectivity in patient outcome prediction, (b) guidance on clinical decision making during perioperative period, (c) better informed consent for patients undergoing hip fracture surgery [2] , and (d) treatment optimisation to improve outcome.
Various scoring tools exist and there is uncertainty as to the most suitable tool for use in hip fracture. The ideal risk scoring tool has the following attributes: simple; ease of use; reproducible; accurate; reliable; objective and available to all patients [2] . The extent to which current hip fracture scoring systems meet these criteria is unclear. This study aims to describe the components, likely clinical utility and degree of validation of published risk scoring tools.
Materials and methods
We searched eight databases; AMED, CINHAL, Clinical Trials.-gov, Cochrane, DARE, EMBASE, MEDLINE, and Web of Science. The review considered all relevant published studies on development and validation of risk stratification tools in patients with fragility hip fracture. Studies were considered using the recommended standards guidelines for reporting systematic reviews of observation studies [3] . All relevant studies worldwide in any language published from 1966 to the 30th of April 2015, inclusive were included in the review. The search strategy is outlined as supplementary data appendix 1.
Study selection and outcome definition
We defined a risk stratification tool as ''a scoring system or model used to predict or adjust for either mortality or morbidity after surgery, and which contains at least two different risk factors'' [1] . Eligible studies were identified by title, abstract and full-text screening independently by the authors and discrepancies resolved by consensus. Manual hand searching of first generation reference lists was performed. Data extraction was independently undertaken by TM and AM on pre-piloted database forms. We extracted data for each study against the following four facets of validity and reliability: (1) development of items: development and validation samples in same or different cohorts; random selection of samples; (2) process for validation: single centre; multicentre; international; (3) metrics of discrimination: AUROC/c-statistics; and (4) metrics of calibration: HosmerLemeshow or Pearson chi-square statistics. Studies were assessed for methodological quality and risk of bias using Altman's [4] framework for assessing internal validity.
Data and statistical analysis
Calibration and discrimination are the two main performance measures used to evaluate individual risk scoring tools. Discrimination was reported using either the AUROC or the concordance (c-) statistic with AUROC of less than 0.7, 0.7-0.9 and greater than 0.9 considered to indicate poor, moderate and high tool performance respectively [1] . As AUROC was not consistently reported, the observed compared to expected outcome ratio (observed/ expected (O/E)), Spearman's rank correlation and chi-squared test were also used to evaluate risk scoring tool performance.
The agreement between observed and predicted outcomes (calibration) was evaluated using Hosmer-Lemeshow or Pearson chi-square statistics. P < 0.05 reflected evidence of lack of fit [1] .
Results
The search produced 15,620 articles, and 680 were eligible for abstract screening (Fig. 1) . Most studies considered at the abstract stage, reported risks for sustaining hip fracture, rather than outcome following hip fracture, and 12 studies were conference abstract presentations with no full published papers and therefore were excluded leaving 43 studies for full text analysis. Of the 43 full text studies sought, 30 met the inclusion criteria with results presented with sufficient data to evaluate the study outcomes (Table 1) . Thirteen full text studies [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] did not have sufficient qualitative or quantitative data relevant to this review, and were excluded. All studies included in this review were cohort studies.
Quality assessment
Quality assessment for eligible studies is outlined in Table 1 . Seven studies were multicentre with a maximum of nine study sites in one study [24] . Selection bias was not observed in the included studies, though ethnic origin was constrained by the demographic of the study country. Heterogeneity among included studies was observed in method of statistical analysis, variation in time frame of outcome measurements, and in the number of models assessed by individual articles.
Validation
Three forms of validation were observed across included studies; (a) internal -validation in split sample of the same study population as tool derivation cohort, (b) external -validation in new cohort unrelated to tool derivation study at a different institute and (c) temporal -validation in new cohort from derivation study but same institution(s). Supplementary data appendix 2 summarises data for commonly used tools and shows how widely each risk stratification tool has been validated and the original tool development cohort.
Types of risk stratification tools
A total of 25 risk stratification tools (supplementary data appendix 3) were reported among all the included studies. Ten of these 24 risk scoring tools were considered in two or more studies (supplementary data appendix 4). The O-POSSUM, NHFS, E-PASS, CCI and ASA were reported in more than three studies each with a total sample of 5975, 13 977, 5832, 6 230 456 and 5411 patients respectively. The other five tools, score by Jiang et al., Risk Model for Delirium (RD), P-POSSUM, Barthel Index and Mini Mental State Examination (MMSE) were reported in two studies each.
Outcomes
The main outcomes (Table 2) were mortality, morbidity and mobility. Timing of outcome measurement ranged from inhospital mortality or length of hospital stay to more than 1 year. Twenty-six studies reported mortality as the main outcome. Inhospital, 30 day and 1 year mortality ranged from 1.6% [25] to 9.7% [8] , 6.6% [26] to 10.9% [20] , and 26% [12] to 30.8% [15] respectively. Sixteen studies reported morbidity, which widely varied from 17.0% [24] to 49.6% [8] .
Discrimination
The area under the receiver operating characteristic curve (AUROC) was presented in 17 studies and ranged from 0.50 to 0.87. Fifteen studies reported AUROC values for scoring systems of >0.7. None of the studies reported AUROC values >0.90.
Calibration
Ten studies reported calibration. Eight calculated calibration using Hosmer-Lemeshow test with P values ranging from 0.00015 [16] to 0.79 [29] . Two studies [14, 18] reported whether the model was of 'good fit' or 'poor fit' without further statistical presentation. Calibration values for one study [22] were not presented in the original paper, but were given by the authors in a subsequent letter [49] .
Risk stratification tools published in more than one study
Preoperative scores
Three clinical scoring systems that use readily available preoperative data were validated in multiple studies; ASA [8, 18, 29] , CCI [7] [8] [9] [10] 12] and NHFS, [10, [26] [27] [28] [29] [30] [31] .
American Society of Anesthesiologists physical score (ASA). The ASA is widely used as a surrogate for operative risk and grades patients according to their chronic physiological state. The three studies which considered ASA found it to be of poor to moderate discriminant accuracy (AUROC varying from 0.60 to 0.71).
Charlson Comorbidity Index (CCI). The CCI is a medical risk prediction tool, which has been adapted for surgical risk stratification. All the studies reported moderate AUROC for CCI on mortality (0.7-0.77) but poor prediction with regards to 90 days mortality (0.59).
Nottingham Hip Fracture Score (NHFS).
The NHFS is a combination of seven independent predictors of mortality. AUROC values reported in three studies 0.72 [29] , 0.73 [31] and 0.77 [10] showing this score to be a moderately discriminatory tool. Calibration is adequate: the original single centre tool development reported P = 0.79 (Hosmer-Lemeshow) [29] and multicentre validation reported P > 0.1 [26] showing adequate 'goodness-of-fit' on performance of this model. One study [27] showed that increasing NHFS was negatively correlated with eventual return-to-home r 2 = 0.949.
Physiological scores (models incorporating pre-and intra-operative scores) POSSUM discrimination (AUROC) ranges from 0.63 to 0.65 for 90 days mortality and ambulation, suggesting poor discrimination [8] . The orthopaedic version (O-POSSUM) has AUROC values ranging 0.62 [8] to 0.74 [21] for mortality, and 0.83 [18] for both mortality and morbidity. However, calibration appeared poor with the observed and expected ratio ranging from 0.12 to 1.19 [18] . The P-POSSUM observed and expected ratio values had a wide range 0.15 [22] and 2.17 [19] for in hospital mortality.
Five studies on E-PASS, [10, [22] [23] [24] [25] reported their results in various forms. AUROC 0.72 and calibration P = 0.103 [10] and O/E values ranged from 0.55 to 1.59 [22] . Four studies observed a significant positive correlation between Physiological Risk Score (PRS) and Comprehensive Risk Score (CRS) to measured outcomes but there was no significant correlation observed between the surgical stress score (SSS) and outcomes. Cost of hospitalisation was reported to be associated with SSS and CRS [23, 25] . All other risk models reported in two or less studies are detailed appendix 3.
Discussion
This study provides a comprehensive review of the current evidence on a variety of risk stratification tools used in hip fracture patients. Of the 25 scoring systems identified, only five had been evaluated in more than two studies, and four outside their original centre. Of these five ASA does not perform well; despite its simplicity [1] it does not appear to be robust enough in this population. Each of the other four tools has arguments for and against its clinical utility; e.g. tool availability and the objectivity of its parameters. Some tools may be perceived as complex and less likely to be part of daily routine use.
Simplicity and availability
The Nottingham Hip Fracture Score and (NHFS) and Charlson Comorbidity Index (CCI) use readily available pre-operative data. They both have reasonable, though not excellent, discriminant characteristics for mortality and morbidity and have been validated external to their original cohort.
The CCI uses well defined comorbidities. It weights these based on severity and assigns each individual an overall risk score presenting the sum of their comorbidity weights [12] . It is a moderately discriminant tool for in-hospital morbidity and 1 year mortality. However calibration is not well described and this limits its ability as an audit tool. Functional ability and confusion (as opposed to dementia) which are known predictors of outcome following hip fracture are not included.
The NHFS is a hip fracture specific score, which has been validated for early hospital discharge [27] , 30-day mortality [29] and 1 year mortality [28] . Its discriminant ability is moderate and has reasonable calibration. All the required data items are routinely collected. It uses the Abbreviated Mental Test Score (AMTS) as its assessment for cognitive impairment which may not be so widely used in countries outside the UK. There are currently no data on regarding the interchangeability of screening tests for cognitive impairment, such as MMSE or clock drawing, in this context. Grp A Hospital discharge Morbidity rates increased linearly with CRS, P = 0.17, P 0.0001 and PRS, P = 0.17, P < 0.0001, but not with SSS, P = 0.01, P = 0. In hospital mortality was correlated with SSS P = À14, P = 0.019, but not with PRS, P = 0.05, P = 0.220 and CRS P = 0.001, P = 0.494 Hirose [25] E-PASS Hospital discharge 20 Spearman correlation Post-operative morbidity rates increased linearly and correlated significantly with (preoperative risk score (PRS)) P = 0.16, P < 0.0001) (comprehensive risk score (CRS) P = 0.18, P < 0.0001) but not surgical stress score (SSS) P = 0.06, P = 0.07) Cost of hospitalisation PRS (R = 0.12, P < 0.0001) SSS (r = 0.44, P < 0.0001) CRS (r = 0.23, P < 0.0001) (Pearson correlation)
1.6 NR Spearman correlation mortality rates correlated with PRS (P = 0.14, P = 0.0001) CRS (P = 0.14, P = 0.0001)but not with SSS (P = À0.03, P = 0.4) Predictor variables of walking ability at discharge was significantly correlated with PRS P = 0.34, P < 0.001, CRS, P = 0.33, P < 0.001 not with SSS P = À0.001, P = 0.495 12 m: walking ability at 1 year was significantly correlated with, PRS, P = 0.41, P < 0.001, CRS, P = 0.40, P < 0.001 not with SSS P = À0.05, P = 0.236 Grp B Hospital discharge the predicted walking ability calculated by the logarithm was significantly correlated with the actual ability at discharge P = 0.60, P < 0.001 and at 12 m: after surgery P = 0.65, P < 0.001 Adunsky [32] MMSE CDT Cognitive-FIM Hospital discharge NR NR P < 0.001 Pearson correlation between the three cognitive tests resulted in values ranging from 0.607 to 0.732 E-PASS and O-POSSUM are comparable in their applicability and limitations. The O-POSSUM is the orthopaedic version of the original POSSUM model. Both models use weighted pre and intraoperative data; hence they cannot be used for preoperative risk prediction. They are also perhaps more complex to score with several variables; the O-POSSUM has 18 variables. E-PASS, O-POSSUM, CCI and NHFS have all been validated internationally [10] .
Reported outcomes
Outcomes in the included studies were heavily biased towards mortality. It is a dichotomous variable that is clearly undesirable, objective, clinically important and easy to measure [50] , and has dependence on the time frame of measurement. Mortality rates at fixed time periods were easily comparable between studies. Morbidity occurred frequently in all studies with a reported incidence of 17-49.6%. Heterogeneity in morbidity definition and classification has been observed among included studies. Most studies did not look at functional outcomes.
Prognostic variables
The range of prognostic variables used by the risk stratification tools is summarised in appendix 5. The items in the scores have face validity: they are all known independent predictors of, or surrogates for, outcome. However, some of these may be somewhat subjective. There are other predictive variables not currently included in the commonly used models (for example, red cell width distribution on admission [51] , albumin [21] levels, and some inflammatory markers [52, 53] ) that may merit future consideration.
Study strengths and limitations
We conducted a comprehensive search strategy with strict adherence to Centre for Reviews and Dissemination (CRD) [3] systematic review guidance. Search strategy, data extraction and quality assessment was performed independently by the authors and findings were confirmed within the team.
However the review has limitations. Heterogeneity observed in this review, within and among studies, could also have influenced our results. There was variation in outcome analysis and outcome measures. Five different statistical measures were used for predictive ability of individual risk score tools, AUROC, r 2 , correlation coefficient, O:E and percentages. This was felt necessary to include all high quality studies, for a comprehensive over view of scoring tools available. Unfortunately this also reduced our ability to perform appropriate comparison among all the models presented. This lack of uniformity could affect clarity of which risk score is superior to the other.
Conclusions and future work
The use of risk prediction scores during the perioperative period has been accepted by clinicians as the norm, influencing important informed decision making, to help optimise individual patients' care and to support audit and service improvement. However, the predictive accuracy of risk scores could be more robust and multinational validation is currently lacking. This review has highlighted both strengths and weaknesses of the currently available risk scoring models. This study noted that all outcome measures outlined were medically oriented. Future work could consider the psychological and social dimensional factors that impede early patient discharge in this patient population.
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